文献速递临床试验与 GCP基础与转化研究

围术期静脉铁剂对复杂瓣膜心脏手术输血需求的影响:随机对照试验方案

The effect of perioperative intravenously administered iron isomaltoside 1000 (Monofer®) on transfusion requirements for patients undergoing complex valvular heart surgery: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-07-04

本研究为前瞻性、单中心、双盲随机对照试验,计划纳入214例再次手术或多瓣膜手术患者,随机分为静脉铁剂组(异麦芽糖铁1000,最大20 mg/kg,术前3天及术后给药)和对照组(生理盐水)。主要终点为出院前输血需求(>1单位浓缩红细胞),次要终点包括延迟通气、急性肾损伤和死亡等。

要点

  • 静脉铁剂可能减少复杂瓣膜手术患者的输血需求。
  • 主要终点为术后至出院输血>1单位浓缩红细胞。
  • 次要终点包括延迟通气、急性肾损伤和死亡。

核心结论

  • 试验旨在明确围术期静脉铁剂对再次或复杂瓣膜手术患者输血需求及临床结局的影响。
  • 并探讨铁调素在静脉铁剂升高血红蛋白中的作用。

研究设计与样本

  • 前瞻性、单中心、双盲随机对照试验,计划纳入214例再次手术或多瓣膜手术患者。
  • 2016年8月至2018年,随机分配至静脉铁剂组或对照组。

关键数值与推荐

  • 静脉铁剂组:异麦芽糖铁1000 mg(最大剂量20 mg/kg),术前3天及术后静脉给药。
  • 对照组:等体积生理盐水。
  • 主要终点:术后至出院输血需求(>1单位浓缩红细胞)。
  • 次要终点:延迟通气、急性肾损伤、死亡等主要并发症。

临床怎么用

  • 若试验证实有效,围术期静脉铁剂可能成为复杂瓣膜手术减少输血的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anemia is a frequent complication after cardiac surgery especially following reoperation due to previous prosthetic valve failure or multiple valve surgery (including combined coronary artery bypass grafting). This trial explores whether intravenously administered iron isomaltoside 1000 (Monofer®) results in better clinical outcomes in patients undergoing complex heart valve surgery who are expected to receive transfusion. METHODS/DESIGN: In this prospective, single-center, double-blinded, randomized controlled trial, 214 patients undergoing reoperation or multiple valve surgery are randomly allocated to either the iron isomaltoside 1000 (IVFe) or the control group from August 2016 to August 2018. The IVFe group receives iron isomaltoside 1000 mg (maximum dose 20 mg/kg) intravenously 3 days before and after the surgery. The control group receives an equivalent volume of normal saline. The primary endpoint is transfusion requirement (more than 1 unit of packed erythrocytes) for postoperative care until discharge and secondary endpoint are major complications, such as delayed ventilator therapy, acute kidney injury, and mortality. Reticulocyte count, plasma hepcidin, iron profiles (serum iron, serum ferritin, total iron-binding capacity, transferrin, transferrin saturation), coagulation profiles, urinary analysis, and chemical profiles are measured for three preoperative baseline-data days and just before surgery, except for hepcidin. After surgery, daily routine basic laboratory tests are measured just before discharge and reticulocyte count, iron profiles, and hepcidin are repeatedly checked for three postoperative days. DISCUSSIONS: From our study, we can clarify the following points: the first is the perioperative IVFe effect on the demand for transfusion, and clinical outcomes in reoperation or complex valve surgery and the second is the role of hepcidin in the effect of IVFe on the hemoglobin level increase. TRIAL REGISTRATION: ClinicalTrials.gov , Identifier: NCT02862665 . Registered on August 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee SH, Shim JK, Soh S, et al. The effect of perioperative intravenously administered iron isomaltoside 1000 (Monofer®) on transfusion requirements for patients undergoing complex valvular heart surgery: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29973224. doi:10.1186/s13063-018-2545-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。